Supraphysiologic goses of levothyroxine as adjunctive therapy in bipolar depression: A randomized, double-blind, placebo-controlled study

Journal of Clinical Psychiatry

Volumn 75, Issue 2, 2014, Pages 162-168

  Stamm, Thomas J ^a   Lewitzka, Ute ^c   Sauer, Cathrin ^c   Pilhatsch, Maximilian ^c   Smolka, Michael N ^c   Koeberle, Ursula ^a,b   Adli, Mazda ^a   Ricken, Roland ^a   Scherk, Harald ^d   Frye, Mark A ^f,g   Juckel, Georg ^e   Assion, Hans Joerg ^e   Gitlin, Michael ^g   Whybrow, Peter C ^g   Bauer, Michael ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Schlosspark Klinik   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e RUHR UNIVERSITY BOCHUM   (Germany)

^f Mayo Clinic College of Medicine   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CITALOPRAM; DULOXETINE; FLUOXETINE; LAMOTRIGINE; LEVOTHYROXINE; LITHIUM CARBONATE; MAPROTILINE; METHYLPHENIDATE; MIRTAZAPINE; MOOD STABILIZER; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PLACEBO; PREGABALIN; QUETIAPINE; REBOXETINE; RISPERIDONE; SERTRALINE; SULPIRIDE; TRANYLCYPROMINE; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE; NEUROLEPTIC AGENT; THYROXINE; TRANQUILIZER;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIA; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SEX DIFFERENCE; THYROTOXICOSIS; TREATMENT RESPONSE; BIOSYNTHESIS; BIPOLAR DISORDER; BLOOD; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; METABOLISM; MIDDLE AGED; PLACEBO EFFECT; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBO EFFECT; SEX FACTORS; THYROXINE; TREATMENT OUTCOME;

EID: 84896875346     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12m08305     Document Type: Article

References (46)

1. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002; 59(6):530-537. doi:10.101/archpsyc.59.6.530 PubMed (Pubitemid 34602935)
2. Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60(3):261-269. doi:10.101/archpsyc.60.3.261 PubMed (Pubitemid 36307437)
3. Perlis RH, Miyahara S, Marangell LB, et al STEP-BD Investigators. Longterm implications of early onset in bipolar disorder: data from the first 1000 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Biol Psychiatry. 2004;55(9):875-881. doi:10.1016/j.biopsych. 204.01.02 PubMed (Pubitemid 38526299)
4. Altshuler LL, Post RM, Black DO, et al. Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study. J Clin Psychiatry. 2006;67(10):1551-1560. doi:10.408/JCP.v67n109 PubMed (Pubitemid 44787437)
5. Ghaemi SN, Hsu DJ, Soldani F, et al. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord. 2003;5(6):421-433. doi:10.1046/j.139- 5618.203.074.x PubMed (Pubitemid 38072244)
6. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356(17): 1711-1722. doi:10.1056/NEJMoa064135 PubMed (Pubitemid 46658703)
7. Bauer M, Ritter P, Grunze H, et al. Treatment options for acute depression in bipolar disorder. Bipolar Disord. 2012;14(suppl 2):37-50. doi:10.1/j.139-5618.2012.091.x PubMed
8. Sidor MM, Macqueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry. 2011;72(2):156-167. doi:10.408/JCP.09r05385gre PubMed
9. Bauer M, Silverman DHS, Schlagenhauf F, et al. Brain glucose metabolism in hypothyroidism: a positron emission tomography study before and after thyroid hormone replacement therapy. J Clin Endocrinol Metab. 2009; 94(8):2922-2929. doi:10.1210/jc.208-235 PubMed
10. Bauer M, Goetz T, Glenn T, et al. The thyroid-brain interaction in thyroid disorders and mood disorders. J Neuroendocrinol. 2008;20(10):1101-1114. doi:10.1/j.1365-2826.208.0174.x PubMed
11. Kirov G, Tredget J, John R, et al. A cross-sectional and a prospective study of thyroid disorders in lithium-treated patients. J Affect Disord. 2005;87(2-3): 313-317. doi:10.1016/j.jad.205.03.010 PubMed (Pubitemid 41039954)
12. Bauer M, Blumentritt H, Finke R, et al. Using ultrasonography to determine thyroid size and prevalence of goiter in lithium-treated patients with affective disorders. J Affect Disord. 2007;104(1-3):45-51. doi:10.1016/j.jad. 207.01.03 PubMed (Pubitemid 350052301)
13. Gau CS, Chang CJ, Tsai FJ, et al. Association between mood stabilizers and hypothyroidism in patients with bipolar disorders: a nested, matched casecontrol study. Bipolar Disord. 2010;12(3):253-263. doi:10.1/j.139-5618.2010. 0814.x PubMed
14. Kupka RW, Nolen WA, Post RM, et al. High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure. Biol Psychiatry. 2002;51(4):305-311. doi:10.1016/S06-323(01)01217-3 PubMed (Pubitemid 34214996)
15. Hillegers MH, Reichart CG, Wals M, et al. Signs of a higher prevalence of autoimmune thyroiditis in female offspring of bipolar parents. Eur Neuropsychopharmacol. 2007;17(6-7):394-399. doi:10.1016/j.euroneuro.206.10.05 PubMed (Pubitemid 46497656)
16. Gyulai L, Bauer M, Bauer MS, et al. Thyroid hypofunction in patients with rapid-cycling bipolar disorder after lithium challenge. Biol Psychiatry. 2003; 53(10):899-905. doi:10.1016/S06-323(02)01573-1 PubMed (Pubitemid 36556175)
17. Frye MA, Denicoff KD, Bryan AL, et al. Association between lower serum free T4 and greater mood instability and depression in lithium-maintained bipolar patients. Am J Psychiatry. 1999;156(12):1909-1914. PubMed
18. Frye MA, Yatham L, Ketter TA, et al. Depressive relapse during lithium treatment associated with increased serum thyroid-stimulating hormone: results from two placebo-controlled bipolar I maintenance studies. Acta Psychiatr Scand. 2009;120(1):10-13. doi:10.1/j.160-047.208.01343.x PubMed
19. Cole DP, Thase ME, Mallinger AG, et al. Slower treatment response in bipolar depression predicted by lower pretreatment thyroid function. Am J Psychiatry. 2002;159(1):116-121. doi:10.176/api.ajp.159.1.16 PubMed (Pubitemid 41070736)
20. Bauer MS, Whybrow PC. Rapid cycling bipolar affective disorder, II: treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch Gen Psychiatry. 1990;47(5):435-440. doi:10.101/archpsyc. 190.018101703506 PubMed (Pubitemid 20161262)
21. Bauer M, Berghöfer A, Bschor T, et al. Supraphysiological doses of l-thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders. Neuropsychopharmacology. 2002;27(4):620-628. PubMed
22. Bauer M, Hellweg R, Gräf KJ, et al. Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacology. 1998;18(6):444-455. doi:10.1016/S0893-13X(97)0181-4 PubMed
23. Bauer M, London ED, Rasgon N, et al. Supraphysiological doses of levothyroxine alter regional cerebral metabolism and improve mood in bipolar depression. Mol Psychiatry. 2005;10(5):456-469. doi:10.1038/sj.mp.401647 PubMed (Pubitemid 40646434)
24. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. doi:10.136/jnp.23.1.56 PubMed
25. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133(5):429-435. doi:10.192/bjp.13.5.429 PubMed (Pubitemid 9006756)
26. Bauer M, Bschor T, Pfennig A, et al; WFSBP Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry. 2007;8(2):67-104. doi:10.1080/ 156297070127829 PubMed (Pubitemid 46690921)
27. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington, DC: American Psychiatric Press, Inc; 1996.
28. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382-389. doi:10.192/bjp.134.4.382 PubMed (Pubitemid 9136500)
29. Bauer M, Baur H, Berghöfer A, et al. Effects of supraphysiological thyroxine administration in healthy controls and patients with depressive disorders. J Affect Disord. 2002;68(2-3):285-294. doi:10.1016/S0165-0327(0)0363- 3 PubMed (Pubitemid 34628334)
30. Rief W, Nestoriuc Y, Weiss S, et al. Meta-analysis of the placebo response in antidepressant trials. J Affect Disord. 2009;118(1-3):1-8. doi:10.1016/j.jad.209.01.029 PubMed
31. Altshuler LL, Bauer M, Frye MA, et al. Does thyroid supplementation accelerate tricyclic antidepressant response? a review and meta-analysis of the literature. Am J Psychiatry. 2001;158(10):1617-1622. doi:10.176/api.ajp.158.10. 1617 PubMed (Pubitemid 32923653)
32. Coppen A, Whybrow PC, Noguera R, et al. The comparative antidepressant value of l-tryptophan and imipramine with and without attempted potentiation by liothyronine. Arch Gen Psychiatry. 1972;26(3):234-241. doi:10.101/archpsyc.1972. 017502104209 PubMed
33. Agid O, Lerer B. Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation. Int J Neuropsychopharmacol. 2003;6(1):41-49. doi:10.1017/S146145702032X PubMed (Pubitemid 36373099)
34. Bauer M, Glenn T, Pilhatsch M, et al. Gender differences in thyroid system function: relevance to bipolar disorder and its treatment. Bipolar Disord. In press.
35. Baldassano CF, Marangell LB, Gyulai L, et al. Gender differences in bipolar disorder: retrospective data from the first 500 STEP-BD participants. Bipolar Disord. 2005;7(5):465-470. doi:10.1/j.139-5618.205.0237.x PubMed (Pubitemid 41419414)
36. Bauer M, Fairbanks L, Berghöfer A, et al. Bone mineral density during maintenance treatment with supraphysiological doses of levothyroxine in affective disorders: a longitudinal study. J Affect Disord. 2004;83(2-3): 183-190. doi:10.1016/j.jad.204.08.01 PubMed (Pubitemid 39536193)
37. Ricken R, Bermpohl F, Schlattmann P, et al. Long-term treatment with supraphysiological doses of thyroid hormone in affective disorders: effects on bone mineral density. J Affect Disord. 2012;136(1-2):e89-e94. doi:10.1016/j.jad.201.06.01 PubMed
38. Whybrow PC, Prange AJ Jr. A hypothesis of thyroid-catecholamine-receptor interaction: its relevance to affective illness. Arch Gen Psychiatry. 1981; 38(1):106-113. doi:10.101/archpsyc.1981.01780260108012 PubMed (Pubitemid 11156719)
39. Bauer M, Heinz A, Whybrow PC. Thyroid hormones, serotonin and mood: of synergy and significance in the adult brain. Mol Psychiatry. 2002;7(2): 140-156. doi:10.1038/sj.mp.40963 PubMed (Pubitemid 34177782)
40. Cleare AJ, McGregor A, O'Keane V. Neuroendocrine e9idence for an association between hypothyroidism, reduced central 5-HT activity and depression. Clin Endocrinol (Oxf). 1995;43(6):713-719. doi:10.1/j.1365-265.195. tb0540.x PubMed (Pubitemid 26016802)
41. Cleare AJ, McGregor A, Chambers SM, et al. Thyroxine replacement increases central 5-hydroxytryptamine activity and reduces depressive symptoms in hypothyroidism. Neuroendocrinology. 1996;64(1):65-69. PubMed (Pubitemid 26184096)
42. Gur E, Lifschytz T, Lerer B, et al. Effects of triiodothyronine and imipramine on basal 5-HT levels and 5-HT1 autoreceptor activity in rat cortex. Eur J Pharmacol. 2002;457(1):37-43. doi:10.1016/S014-29(02)02642-0 PubMed (Pubitemid 35379973)
43. Gur E, Lifschytz T, Van De Kar LD, et al. Effects of triiodothyronine on 5-HT1A and 5-HT1B autoreceptor activity, and postsynaptic 5-HT1A receptor activity, in rat hypothalamus: lack of interaction with imipramine. Psychoneuroendocrinology. 2004;29(9):1172-1183. doi:10.1016/j.psyneuen.204.01.01 PubMed (Pubitemid 38829179)
44. Lifschytz T, Segman R, Shalom G, et al. Basic mechanisms of augmentation of antidepressant effects with thyroid hormone. Curr Drug Targets. 2006; 7(2):203-210. doi:10.2174/138945067515482 PubMed
45. Goodwin FK, Jamison KR. Manic-Depressive Illness. 2nd ed. New York, NY: Oxford University Press; 2007.
46. Grunze H, Vieta E, Goodwin GM, et al; WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010;11(2):81-109. doi:10.3109/1562970903581 PubMed